-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression
While ultimately underpowered, Dr. Giulia Pasello said combination therapy demonstrated an improvement in median PFS compared to chemotherapy alone.
-
Choosing Wisely: Strategies for Navigating Therapeutic Options in Special SCLC Populations
Motoko Tachihara, MD, PhD, addresses various treatment strategies for SCLC populations in an interview with ILCN.
-
The Role of Physiotherapy in Enhancing Lung Cancer Patients’ Quality of Life
Leading experts will outline how genomics, AI, and surgical technology are shaping the next generation of thoracic oncology.
-
Scientific Plenary to Spotlight Innovation and Empowering Future Oncologists
During the session, Drs. Arsela Prelaj, Victor Velculescu, and Lars Konge will address topics that promise to shape the future of thoracic oncology.
-
Test Your Knowledge at the Closing Lunch of the 2025 World Conference on Lung Cancer
Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.
-
Second WCLC 2025 Presidential Symposium Will Cover Different Disciplines in Thoracic Oncology
In addition to recent developments in lung cancer care, attendees will hear from outgoing IASLC President Dr. Paul Van Schil and incoming President Dr. Caicun Zhou.
-
Novel ADC Shows Longest PFS to Date for EGFRm NSCLC
Investigators Wenfeng Fang, MD, PhD, and Fei Zhou, MD, PhD, share results from mono, combination studies of iza-bren. The data will be discussed during an oral abstract session Monday afternoon.
-
Adding Value to Lung Cancer Care: Targeted Therapies
In a Q&A with ILCN, Gisele Fraga Moreira discusses the role of targeted therapies in lung cancer care and managing toxicities with new treatments.
-
The Preclinical Genomics of Lung Cancer Plasticity and Metastasis
Dr. Triparna Sen will explore how shifts in tumor biology—from small cell to non-small cell lung cancer and beyond—fuel plasticity, resistance, and metastasis.